MGNX · Insider Trading
MacroGenics, Inc.
Every open-market purchase and sale reported by MGNX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-07 | Ezio Bonvini | Sr VP, Research & CSO | M | +8,000 | +$20.80K |
| 2026-08-20 | Jeffrey Stuart Peters | Senior VP, GC, and Secretary | Sell | −31,105 | −$129.09K |
| 2026-08-18 | Ezio Bonvini | Sr VP, Research & CSO | M | +40,000 | +$104.00K |
| 2026-05-20 | Margaret Liu | Director | M | +3,750 | — |
| 2026-05-20 | Scott Thomas Jackson | Director | M | +3,750 | — |
| 2026-05-20 | Jay Philip Siegel | Director | M | +3,750 | — |
| 2026-05-20 | Federica F. O'Brien | Director | M | +3,750 | — |
| 2026-05-20 | Karen Jean Ferrante | Director | M | +3,750 | — |
| 2026-05-20 | Scott Koenig | Director | A | +25,750 deriv. | — |
| 2026-05-20 | William K Heiden | Director | M | +3,750 | — |
| 2026-05-20 | Meenu Chhabra | Director | M | +3,750 | — |
| 2026-05-20 | Edward Hurwitz | Director | M | +3,750 | — |
| 2026-05-20 | David C Stump | Director | M | +3,750 | — |
| 2026-02-17 | Beth Ann Smith | VP, Controller & Treasurer | MIXED | +672 | −$723 |
| 2026-02-17 | Jeffrey Stuart Peters | Senior VP, GC, and Secretary | MIXED | +8,185 | −$8.80K |
| 2026-02-17 | Thomas Spitznagel | Sr VP, Technical Ops | MIXED | +7,812 | −$9.44K |
| 2026-02-17 | Scott Koenig | Director | M | +21,165 | — |
| 2026-02-17 | James Karrels | SVP and CFO | MIXED | +9,209 | −$9.90K |
| 2026-02-17 | Eric Blasius Risser | President and CEO | MIXED | +10,232 | −$11.00K |
| 2026-02-17 | Ezio Bonvini | Sr VP, Research & CSO | MIXED | +10,232 | −$11.00K |
| 2026-02-10 | Beth Ann Smith | VP, Controller & Treasurer | MIXED | +2,577 | −$2.94K |
| 2026-02-10 | Scott Koenig | Director | M | +15,831 | — |
| 2026-02-10 | Eric Blasius Risser | President and CEO | MIXED | +10,948 | −$12.46K |
| 2026-02-10 | James Karrels | SVP and CFO | MIXED | +10,027 | −$11.41K |
| 2026-02-10 | Jeffrey Stuart Peters | Senior VP, GC, and Secretary | MIXED | +9,209 | −$10.48K |
| 2026-02-10 | Ezio Bonvini | Sr VP, Research & CSO | MIXED | +11,153 | −$12.70K |
| 2026-02-10 | Thomas Spitznagel | Sr VP, Technical Ops | MIXED | +9,329 | −$10.26K |
| 2025-12-10 | Beth Ann Smith | VP, Controller & Treasurer | A | +25,000 deriv. | — |
| 2025-08-21 | William K Heiden | Director | Buy | +100,000 | +$150.51K |
| 2025-08-19 | Thomas Spitznagel | Sr VP, Technical Ops | A | +30,000 deriv. | — |
| 2025-08-19 | Jeffrey Stuart Peters | Senior VP and General Counsel | A | +30,000 deriv. | — |
| 2025-08-15 | Eric Blasius Risser | President and CEO | A | +550,000 deriv. | — |
| 2025-08-15 | Scott Koenig | Director | M | +52,829 | — |
| 2025-05-22 | Margaret Liu | Director | M | +6,500 | — |
| 2025-05-22 | Meenu Chhabra | Director | M | +6,500 | — |
| 2025-05-22 | Scott Thomas Jackson | Director | M | +6,500 | — |
| 2025-05-22 | Federica F. O'Brien | Director | M | +6,500 | — |
| 2025-05-22 | William K Heiden | Director | M | +6,500 | — |
| 2025-05-22 | Jay Philip Siegel | Director | M | +6,500 | — |
| 2025-05-22 | David C Stump | Director | M | +6,500 | — |
| 2025-05-22 | Karen Jean Ferrante | Director | M | +6,500 | — |
| 2025-05-22 | Edward Hurwitz | Director | M | +6,500 | — |
| 2025-02-19 | James Karrels | SVP, CFO and Secretary | MIXED | +9,208 | −$14.82K |
| 2025-02-19 | Ezio Bonvini | Sr VP, Research & CSO | M | +16,665 | — |
| 2025-02-19 | Stephen L. Eck | Chief Medical Officer | MIXED | +11,723 | −$12.65K |
| 2025-02-19 | Eric Blasius Risser | Chief Operating Officer | MIXED | +10,232 | −$16.47K |
| 2025-02-19 | Scott Koenig | President and CEO | M | +42,329 | — |
| 2025-02-19 | Beth Ann Smith | VP, Controller & Treasurer | MIXED | +672 | −$1.08K |
| 2025-02-19 | Jeffrey Stuart Peters | Senior VP and General Counsel | MIXED | +8,185 | −$13.18K |
| 2025-02-19 | Thomas Spitznagel | Sr VP, Technical Ops | MIXED | +7,812 | −$14.13K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Edward Hurwitz | Director | 1,752,820 | $3.84M |
| Scott Koenig | President and CEO | 1,294,720 | $2.84M |
| James Karrels | SVP and CFO | 306,368 | $670.95K |
| Ezio Bonvini | Sr VP, Research & CSO | 193,799 | $424.42K |
| William K Heiden | Director | 114,750 | $251.30K |
| Eric Blasius Risser | President and CEO | 83,602 | $183.09K |
| Thomas Spitznagel | Sr VP, Technical Ops | 38,543 | $84.41K |
| Stephen L. Eck | Chief Medical Officer | 29,377 | $64.34K |
| Federica F. O'Brien | Director | 14,750 | $32.30K |
| David C Stump | Director | 14,750 | $32.30K |
| Margaret Liu | Director | 14,750 | $32.30K |
| Meenu Chhabra | Director | 14,750 | $32.30K |
| Scott Thomas Jackson | Director | 14,750 | $32.30K |
| Karen Jean Ferrante | Director | 14,750 | $32.30K |
| Jay Philip Siegel | Director | 14,750 | $32.30K |
| Beth Ann Smith | VP, Controller & Treasurer | 12,781 | $27.99K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MGNX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.